EU Fast-Track Success For BioMarin’s Valrox But Not For Amarin’s Vascepa

Filings For Both Products Are Due By Year End

 
• By Maureen Kenny
  
Race_Track_Stopwatch
The EMA is to review BioMarin's planned marketing application more quickly • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography